Plain-English translation of NCT03889639 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple sclerosis research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial tested , a new oral medication, to find the best dose for treating relapsing multiple sclerosis (a form of MS where patients experience flare-ups of symptoms). Participants took the medication daily for 12 weeks, then switched to placebo for 4 weeks, so researchers could compare how well different doses worked and how safe the treatment was. The trial was designed to help doctors understand the right balance between benefit and side effects.
Relapsing multiple sclerosis can be unpredictable and disabling, and current treatments don't work well for everyone. Researchers wanted to test whether this new medication could help reduce flare-ups and slow disease progression, and to figure out which dose would be safest and most effective.
Participants attended a 4-week screening visit that included blood tests and an MRI scan to confirm their eligibility. They then took the medication orally (as tablets) once daily for 12 weeks, followed by placebo tablets for 4 weeks, while researchers monitored them closely. The entire trial lasted 24 weeks and included regular visits to check safety, collect blood samples, and assess how well the treatment was working.
AI-generated summary from trial data · Sep 24, 2026 · Not medical advice
United States